<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00904033</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB00025478</org_study_id>
    <nct_id>NCT00904033</nct_id>
  </id_info>
  <brief_title>Calcitriol, Physical Activity, and Bone Health in Cancer Survivors</brief_title>
  <official_title>A Pilot Study of the Effects of High-Dose Oral Calcitriol and Physical Activity on Bone Health in Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both the calcitriol and exercise interventions are aimed at reducing fracture risk by
      maintaining proper bone density, thereby preventing osteoporotic/osteopenic conditions and
      increasing muscle mass. Both calcitriol and exercise are efficacious in maintaining proper
      bone health and muscle mass among the general population, but little research has been done
      on breast cancer patients and survivors. The combination of calcitriol and exercise, which
      function through different but similar mechanisms, could produce interactive effects in
      reducing fracture risk among breast cancer survivors.

      Hypothesis: A combination of calcitriol along with a structured home-based walking and
      progressive resistance exercise program will be efficacious in preventing bone resorption and
      in increasing bone formation among survivors of invasive breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective

      To collect data on the efficacy and feasibility of a supplementation of calcitriol
      with/without an accompanying structured home-based walking/progressive resistance exercise
      program for improving bone health among breast cancer survivors.

      Secondary Objectives

      To collect data on the efficacy and feasibility of a supplementation of calcitriol
      with/without an accompanying structured home-based walking/progressive resistance exercise
      program for increasing strength among breast cancer survivors.

      To collect data on the efficacy and feasibility of a supplementation of calcitriol
      with/without an accompanying structured home-based walking/progressive resistance exercise
      program for improving skeletal muscle mass among breast cancer survivors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2008</start_date>
  <completion_date type="Actual">January 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Resorption (Exercise)</measure>
    <time_frame>Week 12</time_frame>
    <description>Bone Resorption using Serum NTx (Exercise comparison)
Serum NTx level is used to aid in predicting skeletal response (bone mineral density) to antiresorptive therapy and in monitoring bone resorption changes following initiation of antiresorptive therapy. Elevated levels of serum NTx indicate elevated bone resorption. Elevated bone resorption is the primary cause of agerelated bone loss and that low bone mass often results in osteopenia and is the major cause of osteoporosis. The measurement range is in nanoMoles (NM) Bone Collagen Equivalents (BCE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Resorption (Calcitriol)</measure>
    <time_frame>Week 12</time_frame>
    <description>Bone Resorption using Serum NTx (Calcitriol comparison)
Serum NTx level is used to aid in predicting skeletal response (bone mineral density) to antiresorptive therapy and in monitoring bone resorption changes following initiation of antiresorptive therapy. Elevated levels of serum NTx indicate elevated bone resorption. Elevated bone resorption is the primary cause of agerelated bone loss and that low bone mass often results in osteopenia and is the major cause of osteoporosis. The measurement range is in nanoMoles (nm) Bone Collagen Equivalents (BCE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Formation (Exercise)</measure>
    <time_frame>Week 12</time_frame>
    <description>Bone Formation using Serum BSAP (Exercise comparison)
The Bone-Specific Alkaline Phosphatase (BSAP) assay provides a general index of bone formation and a specific index of total osteoblast activity. BSAP and osteocalcin are the most effective markers of bone formation and are particularly useful for monitoring bone formation therapies and antiresorptive therapies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Formation (Calcitriol)</measure>
    <time_frame>Week 12</time_frame>
    <description>Bone Formation using Serum BSAP (Calcitriol comparison)
The Bone-Specific Alkaline Phosphatase (BSAP) assay provides a general index of bone formation and a specific index of total osteoblast activity. BSAP and osteocalcin are the most effective markers of bone formation and are particularly useful for monitoring bone formation therapies and antiresorptive therapies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Handgrip (kg) Strength - (Exercise)</measure>
    <time_frame>Week 12</time_frame>
    <description>Handgrip (kg) Strength (Exercise comparison)
Hand grip strength can be quantified by measuring the amount of static force that the hand can squeeze around a dynamometer. It is typically measured in kilograms or pounds and varies by sex and age. Normative data for females is AGE 35-39 --&gt; 20.3-34.1kg; AGE 40-44 --&gt; 18.9-32.7kg; AGE 45-49 --&gt; 18.6-32.4kg; AGE 50-54 --&gt; 18.1-31.9kg; AGE 55-59 --&gt; 17.7-31.5kg; AGE 60-64 --&gt; 17.2-31.0kg; AGE 65-69 --&gt; 15.4-27.2kg; AGE 70-99 --&gt; 14.7-24.5kg. Values less than the normal range are considered weak strength. Values greater than the normal range are considered strong strength.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip (kg) Strength - (Calcitriol)</measure>
    <time_frame>Week 12</time_frame>
    <description>Handgrip (kg) Strength - (Calcitriol comparison)
Hand grip strength can be quantified by measuring the amount of static force that the hand can squeeze around a dynamometer. It is typically measured in kilograms or pounds and varies by sex and age. Normative data for females is AGE 35-39 --&gt; 20.3-34.1kg; AGE 40-44 --&gt; 18.9-32.7kg; AGE 45-49 --&gt; 18.6-32.4kg; AGE 50-54 --&gt; 18.1-31.9kg; AGE 55-59 --&gt; 17.7-31.5kg; AGE 60-64 --&gt; 17.2-31.0kg; AGE 65-69 --&gt; 15.4-27.2kg; AGE 70-99 --&gt; 14.7-24.5kg. Values less than the normal range are considered weak strength. Values greater than the normal range are considered strong strength.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (Exercise)</measure>
    <time_frame>Week 12</time_frame>
    <description>Body Mass Index (BMI) - (Exercise Comparison)
Measure Description: Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters. Values below 18.5 represent &quot;Underweight&quot;, 18.5 to 24.9 represent &quot;Normal or Healthy Weight&quot;, 25.0 to 29.9 represent &quot;Overweight&quot; and 30.0 and above represent &quot;Obese&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (Calcitriol)</measure>
    <time_frame>Week 12</time_frame>
    <description>Body Mass Index(BMI) - (Calcitriol comparison)
Measure Description: Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters. Values below 18.5 represent &quot;Underweight&quot;, 18.5 to 24.9 represent &quot;Normal or Healthy Weight&quot;, 25.0 to 29.9 represent &quot;Overweight&quot; and 30.0 and above represent &quot;Obese&quot;.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Bone and Bones</condition>
  <arm_group>
    <arm_group_label>Multivitamin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multivitamin used as control group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise consisting of progressive walking and resistance band training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcitriol pill taken once per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcitriol and Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcitriol pill taken once per week plus Exercise consisting of progressive walking and resistance band training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>Calcitriol tablet taken once per week.</description>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_label>Calcitriol and Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Exercise consisting of progressive walking and resistance band training</description>
    <arm_group_label>Calcitriol and Exercise</arm_group_label>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multivitamin</intervention_name>
    <arm_group_label>Multivitamin</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be female.

          -  Women of child-bearing potential (i.e. women who are pre-menopausal or not surgically
             sterile) must use acceptable contraceptive methods (abstinence, intrauterine device
             (IUD), or double barrier device) and must have a negative serum or urine pregnancy
             test within 1 week prior to beginning treatment on this trial. Contraceptive use needs
             to be continued at least 1 month after the trial has ended.

          -  Must provide informed consent.

          -  Must be willing to discontinue use of calcium and/or vitamin D supplements.

          -  Participants must have an ionized serum calcium level within normal limits
             (1.19-1.29mmol/L) and a total corrected serum calcium of &lt; 10.2mg/dl.

          -  Must have a functional capacity rating of ≤ 2 on the Eastern Cooperative Oncology
             Group (ECOG) performance status when assessed at baseline.

          -  Must have the approval of their treating physician (or physician's nurse practitioner
             or physician's assistant) to participate in sub-maximal physiological fitness testing
             and a low to moderate home-based walking and progressive resistance exercise program
             and to receive the 12-week supplementation of calcitriol 45 μg. Participants assigned
             to either of the calcitriol treatment arms will be instructed to stop taking calcium
             and/or vitamin D supplements.

          -  Must be less than five years from the diagnosis of breast cancer and have received
             chemotherapy, radiation therapy, and/or hormonal therapy. Chemotherapy and radiation
             therapy, if received, must have been completed prior to study enrollment. Hormonal
             therapy may be ongoing.

        Exclusion Criteria:

          -  Subjects with life-threatening conditions that would preclude them from breast cancer
             treatment including chronic cardiac failure, which is unstable despite medication use,
             uncontrolled hypertension, uncontrolled diabetes mellitus, or unstable coronary artery
             disease.

          -  Patients who had a myocardial infarction within the past year.

          -  Patients with severe metabolic disorders, which includes phenylketonuria (PKU),
             homocystinuria, and Fabry's disease, that would preclude them from taking calcitriol.

          -  Patients with impaired renal function (CRCL &lt; 60 mL/min) or who had kidney stones
             (calcium salt) within the past 5 years.

          -  Patients with hypercalcemia (corrected serum Ca &gt; 10.2 mg/dl) or a history of
             hypercalcemia or vitamin D toxicity.

          -  Patients currently taking calcium supplements or aluminum-based antacids must be
             willing to discontinue their use if they are to enroll in the study.

          -  Patients currently taking vitamin D supplements must immediately discontinue their use
             if they are to enroll in the study.

          -  Patients with a known sensitivity to calcitriol.

          -  Women who are pregnant or lactating.

          -  Previously verified diagnosed of osteoporosis.

          -  Women on antiresorptive drugs (e.g. bisphosphonates) within the past year.

          -  Patients not capable of participating in an exercise intervention due to severe knee
             arthrosis or ligament/cartilage injuries of the lower extremities.

          -  Women currently using oral contraception.

          -  Women with malabsorptive syndromes (i.e. cystic fibrosis, chronic pancreatitis) or
             taking medications that decrease the absorption of fat soluble vitamins (i.e.
             Orlistat, Questran).

          -  Participants assigned to calcitriol who are routinely taking a multivitamin supplement
             may continue the supplement as long as the amount of vitamin D in the supplement is
             not in excess of the RDA (recommended daily allowance) of 400 IU or 10 μg. If they are
             not taking a multivitamin supplement, they will be asked to not start supplementation
             while on study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luke J Peppone, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 15, 2009</study_first_submitted>
  <study_first_submitted_qc>May 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2009</study_first_posted>
  <results_first_submitted>February 14, 2019</results_first_submitted>
  <results_first_submitted_qc>April 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2019</results_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Luke Peppone</investigator_full_name>
    <investigator_title>Research Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 4, 2009</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT00904033/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Multivitamin</title>
          <description>Multivitamin used as control group.
Multivitamin</description>
        </group>
        <group group_id="P2">
          <title>Exericse</title>
          <description>Exercise consisting of progressive walking and resistance band training.
Exercise: Exercise consisting of progressive walking and resistance band training</description>
        </group>
        <group group_id="P3">
          <title>Calcitriol</title>
          <description>Calcitriol pill taken once per week.
Calcitriol: Calcitriol tablet taken once per week.</description>
        </group>
        <group group_id="P4">
          <title>Calcitriol and Exercise</title>
          <description>Calcitriol pill taken once per week plus Exercise consisting of progressive walking and resistance band training.
Calcitriol: Calcitriol tablet taken once per week.
Exercise: Exercise consisting of progressive walking and resistance band training</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to obtain final blood draw</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Multivitamin</title>
          <description>Multivitamin used as control group.
Multivitamin</description>
        </group>
        <group group_id="B2">
          <title>Exericse</title>
          <description>Exercise consisting of progressive walking and resistance band training.
Exercise: Exercise consisting of progressive walking and resistance band training</description>
        </group>
        <group group_id="B3">
          <title>Calcitriol</title>
          <description>Calcitriol pill taken once per week.
Calcitriol: Calcitriol tablet taken once per week.</description>
        </group>
        <group group_id="B4">
          <title>Calcitriol and Exercise</title>
          <description>Calcitriol pill taken once per week plus Exercise consisting of progressive walking and resistance band training.
Calcitriol: Calcitriol tablet taken once per week.
Exercise: Exercise consisting of progressive walking and resistance band training</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" spread="8.2"/>
                    <measurement group_id="B2" value="55.8" spread="6.7"/>
                    <measurement group_id="B3" value="52.0" spread="6.8"/>
                    <measurement group_id="B4" value="55.1" spread="8.7"/>
                    <measurement group_id="B5" value="53.5" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Married</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Single/Divorced/Widowed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Premenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Postmenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hormonal Therapy</title>
          <population>Subject did not received hormone therapy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Tamoxifen</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Aromatase Inhibitor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of Cancer</title>
          <description>Stage 0. This stage describes cancer in situ, which means “in place.” Stage 0 cancers are located in the place they started and have not spread to nearby tissues.
Stage I. This stage is usually a small cancer that has not grown deeply into nearby tissues.
Stage II and Stage III. In general, these 2 stages indicate larger cancers that have grown more deeply into nearby tissue. They may have also spread to lymph nodes but not to other parts of the body.
Stage IV. This stage means that the cancer has spread to other organs or parts of the body.
Stage 0 is best, Stage IV is worst.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 / I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Radiotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Cardiovascular Exercise</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Resistance Training</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Measure Description: Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters. Values below 18.5 represent &quot;Underweight&quot;, 18.5 to 24.9 represent &quot;Normal or Healthy Weight&quot;, 25.0 to 29.9 represent &quot;Overweight&quot; and 30.0 and above represent &quot;Obese&quot;.</description>
          <population>There were 5 subjects who did not have a body weight available (4 subjects in the multivitamin arm and 1 subject in the Calcitriol and Exercise arm) and therefore a BMI was not possible to calculate.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="6.0"/>
                    <measurement group_id="B2" value="32.4" spread="7.5"/>
                    <measurement group_id="B3" value="28.4" spread="5.5"/>
                    <measurement group_id="B4" value="28.1" spread="3.6"/>
                    <measurement group_id="B5" value="29.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum NTx - Bone Resorption</title>
          <description>Serum NTx level is used to aid in predicting skeletal response (bone mineral density) to antiresorptive therapy and in monitoring bone resorption changes following initiation of antiresorptive therapy. The measurement range is in nanoMoles (nm) Bone Collagen Equivalents (BCE).</description>
          <population>Serum NTx not recorded for two subjects in the Calcitriol and Exercise arm because their values were out of range and were not used per the instructions of the assay kit used for Serum NTx analysis.</population>
          <units>nm BCE</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="9"/>
                    <count group_id="B5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.2" spread="10.0"/>
                    <measurement group_id="B2" value="11.6" spread="5.7"/>
                    <measurement group_id="B3" value="13.4" spread="8.1"/>
                    <measurement group_id="B4" value="14.4" spread="9.5"/>
                    <measurement group_id="B5" value="12.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum BSAP - Bone Formation</title>
          <description>The Bone-Specific Alkaline Phosphatase (BSAP) assay provides a general index of bone formation and a specific index of total osteoblast activity. BSAP and osteocalcin are the most effective markers of bone formation and are particularly useful for monitoring bone formation therapies and antiresorptive therapies.</description>
          <population>Serum BSAP not recorded for 1 subject in the Calcitriol and Exercise arm because the values were out of range and were not used per the instructions of the Serum BSAP assay kit.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.2" spread="7.1"/>
                    <measurement group_id="B2" value="13.8" spread="7.2"/>
                    <measurement group_id="B3" value="12.2" spread="7.4"/>
                    <measurement group_id="B4" value="12.0" spread="5.6"/>
                    <measurement group_id="B5" value="12.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum BMOI - Bone Metabolism Index</title>
          <description>BMOI is defined as follows:
ΔZ BSAP − ΔZ NTx, where ZBSAP = (BSAPObserved–BSAPμ at baseline)/σ (standard deviation) at baseline, and ZNTx = (NTxObserved–NTxμ at baseline)/σ at baseline. A positive number for the BMOI indicates a net bone gain: i.e., resorption decreased and formation increased over the course of the intervention. A negative number for the BMOI indicates net bone loss: i.e., resorption increased and formation decreased over the course of the intervention.</description>
          <population>Serum BMOI not recorded for two subjects in the Calcitriol and Exercise arm because their values were out of range and were not used per the instructions of the Serum BMOI assay kit.</population>
          <units>Z-Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="9"/>
                    <count group_id="B5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.03" spread="1.25"/>
                    <measurement group_id="B2" value="0.34" spread="1.05"/>
                    <measurement group_id="B3" value="-0.12" spread="1.44"/>
                    <measurement group_id="B4" value="-0.26" spread="0.96"/>
                    <measurement group_id="B5" value="0.01" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Resorption (Exercise)</title>
        <description>Bone Resorption using Serum NTx (Exercise comparison)
Serum NTx level is used to aid in predicting skeletal response (bone mineral density) to antiresorptive therapy and in monitoring bone resorption changes following initiation of antiresorptive therapy. Elevated levels of serum NTx indicate elevated bone resorption. Elevated bone resorption is the primary cause of agerelated bone loss and that low bone mass often results in osteopenia and is the major cause of osteoporosis. The measurement range is in nanoMoles (NM) Bone Collagen Equivalents (BCE).</description>
        <time_frame>Week 12</time_frame>
        <population>No Exercise group consists of Multivitamin and Calcitriol arms N=20; Exercise group consists of Exercise and Calcitriol+Exercise arms N=19**
** 2 subjects have missing data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>No Exercise</title>
            <description>Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week</description>
          </group>
          <group group_id="O2">
            <title>Exercise</title>
            <description>Exercise Arm: Exercise consisting of progressive walking and resistance band training
Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Resorption (Exercise)</title>
          <description>Bone Resorption using Serum NTx (Exercise comparison)
Serum NTx level is used to aid in predicting skeletal response (bone mineral density) to antiresorptive therapy and in monitoring bone resorption changes following initiation of antiresorptive therapy. Elevated levels of serum NTx indicate elevated bone resorption. Elevated bone resorption is the primary cause of agerelated bone loss and that low bone mass often results in osteopenia and is the major cause of osteoporosis. The measurement range is in nanoMoles (NM) Bone Collagen Equivalents (BCE).</description>
          <population>No Exercise group consists of Multivitamin and Calcitriol arms N=20; Exercise group consists of Exercise and Calcitriol+Exercise arms N=19**
** 2 subjects have missing data for this outcome.</population>
          <units>nm BCE</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="1.656"/>
                    <measurement group_id="O2" value="14.7" spread="1.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>ANCOVA</method>
            <method_desc>Main Effects Results only for No Exercise vs Exercise</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Resorption (Calcitriol)</title>
        <description>Bone Resorption using Serum NTx (Calcitriol comparison)
Serum NTx level is used to aid in predicting skeletal response (bone mineral density) to antiresorptive therapy and in monitoring bone resorption changes following initiation of antiresorptive therapy. Elevated levels of serum NTx indicate elevated bone resorption. Elevated bone resorption is the primary cause of agerelated bone loss and that low bone mass often results in osteopenia and is the major cause of osteoporosis. The measurement range is in nanoMoles (nm) Bone Collagen Equivalents (BCE).</description>
        <time_frame>Week 12</time_frame>
        <population>No Calcitriol group consists of Multivitamin arm and Exercise arm N=20; Calcitriol group consists of Calcitriol and Calcitriol+Exercise arms N=19**
** 2 subjects have missing data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>No Calcitriol</title>
            <description>Multivitamin Arm + Exercise Arm:Exercise consisting of progressive walking and resistance band training</description>
          </group>
          <group group_id="O2">
            <title>Calcitriol</title>
            <description>Calcitriol Arm: Calcitriol pill taken once per week
and
Calcitriol+Exercise Arm:Exercise consisting of progressive walking and resistance band training</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Resorption (Calcitriol)</title>
          <description>Bone Resorption using Serum NTx (Calcitriol comparison)
Serum NTx level is used to aid in predicting skeletal response (bone mineral density) to antiresorptive therapy and in monitoring bone resorption changes following initiation of antiresorptive therapy. Elevated levels of serum NTx indicate elevated bone resorption. Elevated bone resorption is the primary cause of agerelated bone loss and that low bone mass often results in osteopenia and is the major cause of osteoporosis. The measurement range is in nanoMoles (nm) Bone Collagen Equivalents (BCE).</description>
          <population>No Calcitriol group consists of Multivitamin arm and Exercise arm N=20; Calcitriol group consists of Calcitriol and Calcitriol+Exercise arms N=19**
** 2 subjects have missing data for this outcome.</population>
          <units>nm BCE</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="1.785"/>
                    <measurement group_id="O2" value="15.0" spread="1.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Formation (Exercise)</title>
        <description>Bone Formation using Serum BSAP (Exercise comparison)
The Bone-Specific Alkaline Phosphatase (BSAP) assay provides a general index of bone formation and a specific index of total osteoblast activity. BSAP and osteocalcin are the most effective markers of bone formation and are particularly useful for monitoring bone formation therapies and antiresorptive therapies.</description>
        <time_frame>Week 12</time_frame>
        <population>No Exercise group consists of Multivitamin and Calcitriol arms N=20; Exercise group consists of Exercise and Calcitriol+Exercise arms N=20**
**1 subject has missing data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>No Exercise</title>
            <description>Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week</description>
          </group>
          <group group_id="O2">
            <title>Exercise</title>
            <description>Exercise Arm: Exercise consisting of progressive walking and resistance band training
Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Formation (Exercise)</title>
          <description>Bone Formation using Serum BSAP (Exercise comparison)
The Bone-Specific Alkaline Phosphatase (BSAP) assay provides a general index of bone formation and a specific index of total osteoblast activity. BSAP and osteocalcin are the most effective markers of bone formation and are particularly useful for monitoring bone formation therapies and antiresorptive therapies.</description>
          <population>No Exercise group consists of Multivitamin and Calcitriol arms N=20; Exercise group consists of Exercise and Calcitriol+Exercise arms N=20**
**1 subject has missing data for this outcome.</population>
          <units>ng/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="1.513"/>
                    <measurement group_id="O2" value="14.7" spread="0.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Formation (Calcitriol)</title>
        <description>Bone Formation using Serum BSAP (Calcitriol comparison)
The Bone-Specific Alkaline Phosphatase (BSAP) assay provides a general index of bone formation and a specific index of total osteoblast activity. BSAP and osteocalcin are the most effective markers of bone formation and are particularly useful for monitoring bone formation therapies and antiresorptive therapies.</description>
        <time_frame>Week 12</time_frame>
        <population>No Calcitriol group consists of Multivitamin arm and Exercise arm N=20; Calcitriol group consists of Calcitriol and Calcitriol+Exercise arms N=20**
** 1 subject has missing data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>No Calcitriol</title>
            <description>Multivitamin Arm + Exercise Arm:Exercise consisting of progressive walking and resistance band training</description>
          </group>
          <group group_id="O2">
            <title>Calcitriol</title>
            <description>Calcitriol Arm: Calcitriol pill taken once per week
and
Calcitriol+ Exercise Arm:Exercise consisting of progressive walking and resistance band training</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Formation (Calcitriol)</title>
          <description>Bone Formation using Serum BSAP (Calcitriol comparison)
The Bone-Specific Alkaline Phosphatase (BSAP) assay provides a general index of bone formation and a specific index of total osteoblast activity. BSAP and osteocalcin are the most effective markers of bone formation and are particularly useful for monitoring bone formation therapies and antiresorptive therapies.</description>
          <population>No Calcitriol group consists of Multivitamin arm and Exercise arm N=20; Calcitriol group consists of Calcitriol and Calcitriol+Exercise arms N=20**
** 1 subject has missing data for this outcome.</population>
          <units>ng/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="1.268"/>
                    <measurement group_id="O2" value="16.3" spread="0.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip (kg) Strength - (Exercise)</title>
        <description>Handgrip (kg) Strength (Exercise comparison)
Hand grip strength can be quantified by measuring the amount of static force that the hand can squeeze around a dynamometer. It is typically measured in kilograms or pounds and varies by sex and age. Normative data for females is AGE 35-39 --&gt; 20.3-34.1kg; AGE 40-44 --&gt; 18.9-32.7kg; AGE 45-49 --&gt; 18.6-32.4kg; AGE 50-54 --&gt; 18.1-31.9kg; AGE 55-59 --&gt; 17.7-31.5kg; AGE 60-64 --&gt; 17.2-31.0kg; AGE 65-69 --&gt; 15.4-27.2kg; AGE 70-99 --&gt; 14.7-24.5kg. Values less than the normal range are considered weak strength. Values greater than the normal range are considered strong strength.</description>
        <time_frame>Week 12</time_frame>
        <population>No Exercise group consists of Multivitamin and Calcitriol arms N=14*; Exercise group consists of Exercise and Calcitriol+Exercise arms N=17** * 6 subjects have missing data for this outcome.
** 4 subjects have missing data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>No Exercise</title>
            <description>Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week</description>
          </group>
          <group group_id="O2">
            <title>Exercise</title>
            <description>Exercise Arm: Exercise consisting of progressive walking and resistance band training
Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip (kg) Strength - (Exercise)</title>
          <description>Handgrip (kg) Strength (Exercise comparison)
Hand grip strength can be quantified by measuring the amount of static force that the hand can squeeze around a dynamometer. It is typically measured in kilograms or pounds and varies by sex and age. Normative data for females is AGE 35-39 --&gt; 20.3-34.1kg; AGE 40-44 --&gt; 18.9-32.7kg; AGE 45-49 --&gt; 18.6-32.4kg; AGE 50-54 --&gt; 18.1-31.9kg; AGE 55-59 --&gt; 17.7-31.5kg; AGE 60-64 --&gt; 17.2-31.0kg; AGE 65-69 --&gt; 15.4-27.2kg; AGE 70-99 --&gt; 14.7-24.5kg. Values less than the normal range are considered weak strength. Values greater than the normal range are considered strong strength.</description>
          <population>No Exercise group consists of Multivitamin and Calcitriol arms N=14*; Exercise group consists of Exercise and Calcitriol+Exercise arms N=17** * 6 subjects have missing data for this outcome.
** 4 subjects have missing data for this outcome.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="1.633"/>
                    <measurement group_id="O2" value="27.8" spread="0.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip (kg) Strength - (Calcitriol)</title>
        <description>Handgrip (kg) Strength - (Calcitriol comparison)
Hand grip strength can be quantified by measuring the amount of static force that the hand can squeeze around a dynamometer. It is typically measured in kilograms or pounds and varies by sex and age. Normative data for females is AGE 35-39 --&gt; 20.3-34.1kg; AGE 40-44 --&gt; 18.9-32.7kg; AGE 45-49 --&gt; 18.6-32.4kg; AGE 50-54 --&gt; 18.1-31.9kg; AGE 55-59 --&gt; 17.7-31.5kg; AGE 60-64 --&gt; 17.2-31.0kg; AGE 65-69 --&gt; 15.4-27.2kg; AGE 70-99 --&gt; 14.7-24.5kg. Values less than the normal range are considered weak strength. Values greater than the normal range are considered strong strength.</description>
        <time_frame>Week 12</time_frame>
        <population>No Calcitriol group consists of Multivitamin arm and Exercise arm N=14*; Calcitriol group consists of Calcitriol and Calcitriol+Exercise arms N=17** * 6 subjects have missing data for this outcome.
** 4 subjects have missing data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>No Calcitriol</title>
            <description>Multivitamin Arm + Exercise Arm:Exercise consisting of progressive walking and resistance band training</description>
          </group>
          <group group_id="O2">
            <title>Calcitriol</title>
            <description>Calcitriol Arm: Calcitriol pill taken once per week
and
Calcitriol+Exercise Arm:Exercise consisting of progressive walking and resistance band training</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip (kg) Strength - (Calcitriol)</title>
          <description>Handgrip (kg) Strength - (Calcitriol comparison)
Hand grip strength can be quantified by measuring the amount of static force that the hand can squeeze around a dynamometer. It is typically measured in kilograms or pounds and varies by sex and age. Normative data for females is AGE 35-39 --&gt; 20.3-34.1kg; AGE 40-44 --&gt; 18.9-32.7kg; AGE 45-49 --&gt; 18.6-32.4kg; AGE 50-54 --&gt; 18.1-31.9kg; AGE 55-59 --&gt; 17.7-31.5kg; AGE 60-64 --&gt; 17.2-31.0kg; AGE 65-69 --&gt; 15.4-27.2kg; AGE 70-99 --&gt; 14.7-24.5kg. Values less than the normal range are considered weak strength. Values greater than the normal range are considered strong strength.</description>
          <population>No Calcitriol group consists of Multivitamin arm and Exercise arm N=14*; Calcitriol group consists of Calcitriol and Calcitriol+Exercise arms N=17** * 6 subjects have missing data for this outcome.
** 4 subjects have missing data for this outcome.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="1.441"/>
                    <measurement group_id="O2" value="27.1" spread="0.804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (Exercise)</title>
        <description>Body Mass Index (BMI) - (Exercise Comparison)
Measure Description: Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters. Values below 18.5 represent &quot;Underweight&quot;, 18.5 to 24.9 represent &quot;Normal or Healthy Weight&quot;, 25.0 to 29.9 represent &quot;Overweight&quot; and 30.0 and above represent &quot;Obese&quot;.</description>
        <time_frame>Week 12</time_frame>
        <population>No Exercise group consists of Multivitamin and Calcitriol arms N=16*; Exercise group consists of Exercise and Calcitriol+Exercise arms N=20** *4 subjects have missing data for this outcome.
**1 subject has missing data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>No Exercise</title>
            <description>Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week</description>
          </group>
          <group group_id="O2">
            <title>Exercise</title>
            <description>Exercise Arm: Exercise consisting of progressive walking and resistance band training
Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (Exercise)</title>
          <description>Body Mass Index (BMI) - (Exercise Comparison)
Measure Description: Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters. Values below 18.5 represent &quot;Underweight&quot;, 18.5 to 24.9 represent &quot;Normal or Healthy Weight&quot;, 25.0 to 29.9 represent &quot;Overweight&quot; and 30.0 and above represent &quot;Obese&quot;.</description>
          <population>No Exercise group consists of Multivitamin and Calcitriol arms N=16*; Exercise group consists of Exercise and Calcitriol+Exercise arms N=20** *4 subjects have missing data for this outcome.
**1 subject has missing data for this outcome.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="0.312"/>
                    <measurement group_id="O2" value="30.2" spread="0.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (Calcitriol)</title>
        <description>Body Mass Index(BMI) - (Calcitriol comparison)
Measure Description: Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters. Values below 18.5 represent &quot;Underweight&quot;, 18.5 to 24.9 represent &quot;Normal or Healthy Weight&quot;, 25.0 to 29.9 represent &quot;Overweight&quot; and 30.0 and above represent &quot;Obese&quot;.</description>
        <time_frame>Week 12</time_frame>
        <population>No Calcitriol group consists of Multivitamin arm and Exercise arm N=16*; Calcitriol group consists of Calcitriol and Calcitriol+Exercise arms N=20** * 4 subjects have missing data for this outcome.
** 1 subject has missing data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>No Calcitriol</title>
            <description>Multivitamin Arm + Exercise Arm:Exercise consisting of progressive walking and resistance band training</description>
          </group>
          <group group_id="O2">
            <title>Calcitriol</title>
            <description>Calcitriol Arm: Calcitriol pill taken once per week
and
Calcitriol+Exercise Arm:Exercise consisting of progressive walking and resistance band training</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (Calcitriol)</title>
          <description>Body Mass Index(BMI) - (Calcitriol comparison)
Measure Description: Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters. Values below 18.5 represent &quot;Underweight&quot;, 18.5 to 24.9 represent &quot;Normal or Healthy Weight&quot;, 25.0 to 29.9 represent &quot;Overweight&quot; and 30.0 and above represent &quot;Obese&quot;.</description>
          <population>No Calcitriol group consists of Multivitamin arm and Exercise arm N=16*; Calcitriol group consists of Calcitriol and Calcitriol+Exercise arms N=20** * 4 subjects have missing data for this outcome.
** 1 subject has missing data for this outcome.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="0.284"/>
                    <measurement group_id="O2" value="30.1" spread="0.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Multivitamin</title>
          <description>Multivitamin used as control group.
Multivitamin</description>
        </group>
        <group group_id="E2">
          <title>Exericse</title>
          <description>Exercise consisting of progressive walking and resistance band training.
Exercise: Exercise consisting of progressive walking and resistance band training</description>
        </group>
        <group group_id="E3">
          <title>Calcitriol</title>
          <description>Calcitriol pill taken once per week.
Calcitriol: Calcitriol tablet taken once per week.</description>
        </group>
        <group group_id="E4">
          <title>Calcitriol and Exercise</title>
          <description>Calcitriol pill taken once per week plus Exercise consisting of progressive walking and resistance band training.
Calcitriol: Calcitriol tablet taken once per week.
Exercise: Exercise consisting of progressive walking and resistance band training</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia - Grade 1</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Creatinine Elevation - Grade 1</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperkalemia - Grade 1</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypernatremia - Grade 1</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypergycemia - Grade 1</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperglycemia - Grade 2</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood Urea Nitrogen Elevation - Grade 1</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Luke J Peppone, PhD, MPH</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-275-7827</phone>
      <email>Luke_Peppone@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

